Metribolone (methyltrienolone) derivative of trenbolone (trienolone) profile

akn

Musclechemistry Member
<!--[if gte mso 9]><xml> <w:WordDocument> <w:View>Normal</w:View> <w:Zoom>0</w:Zoom> <w:TrackMoves/> <w:TrackFormatting/> <w:punctuationKerning/> <w:ValidateAgainstSchemas/> <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid> <w:IgnoreMixedContent>false</w:IgnoreMixedContent> <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText> <w:DoNotPromoteQF/> <w:LidThemeOther>EN-US</w:LidThemeOther> <w:LidThemeAsian>X-NONE</w:LidThemeAsian> <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript> <w:Compatibility> <w:BreakWrappedTables/> <w:SnapToGridInCell/> <w:WrapTextWithPunct/> <w:UseAsianBreakRules/> <w:DontGrowAutofit/> <w:SplitPgBreakAndParaMark/> <w:DontVertAlignCellWithSp/> <w:DontBreakConstrainedForcedTables/> <w:DontVertAlignInTxbx/> <w:Word11KerningPairs/> <w:CachedColBalance/> <w:UseFELayout/> </w:Compatibility> <w:DoNotOptimizeForBrowser/> <m:mathPr> <m:mathFont m:val="Cambria Math"/> <m:brkBin m:val="before"/> <m:brkBinSub m:val="--"/> <m:smallFrac m:val="off"/> <m:dispDef/> <m:lMargin m:val="0"/> <m:rMargin m:val="0"/> <m:defJc m:val="centerGroup"/> <m:wrapIndent m:val="1440"/> <m:intLim m:val="subSup"/> <m:naryLim m:val="undOvr"/> </m:mathPr></w:WordDocument> </xml><![endif]--> [FONT=&quot]Description:[/FONT]
[FONT=&quot]Methyltrienolone is one of the strongest oral anabolic[/FONT]
[FONT=&quot]steroids ever produced. This agent is a derivative of[/FONT]

[FONT=&quot]trenbolone (trienolone), which has been c-17 alpha alkylated[/FONT]
[FONT=&quot]to allow for oral administration. This modification has[/FONT]
[FONT=&quot]created a steroid that is significantly stronger than its nonmethylated[/FONT]
[FONT=&quot]cousin. Its potency has been measured to be[/FONT]
[FONT=&quot]anywhere from 120-300 times greater than that of[/FONT]
[FONT=&quot]methyltestosterone, with greater dissociation between[/FONT]
[FONT=&quot]anabolic and androgenic effects.535 536 Milligram for[/FONT]
[FONT=&quot]milligram methyltrienolone is a more active steroid than any[/FONT]
[FONT=&quot]agent sold on the commercial market, requiring doses as little[/FONT]
[FONT=&quot]as .5-1 milligram per day to notice a strong anabolic effect.[/FONT]
[FONT=&quot]Its potency is only matched by its relative toxicity, however,[/FONT]
[FONT=&quot]which has limited its modern use to that of laboratory[/FONT]
[FONT=&quot]research only.[/FONT]
[FONT=&quot]History:[/FONT]
[FONT=&quot]Methyltrienolone was first described in 1965.537 It was[/FONT]
[FONT=&quot]immediately identified as an extremely potent anabolic agent,[/FONT]
[FONT=&quot]far more potent than the commercially available agents of the[/FONT]
[FONT=&quot]time. In spite of its high relative activity, however,[/FONT]
[FONT=&quot]methyltrienolone has seen very limited use in humans. It was[/FONT]
[FONT=&quot]used clinically during the late 1960’s and early ’70’s, most[/FONT]
[FONT=&quot]notably in the treatment of advanced breast cancer. Here, its[/FONT]
[FONT=&quot]exceedingly strong anabolic/androgenic action helps the drug[/FONT]
[FONT=&quot]counter the local effects of endogenous estrogens, lending it[/FONT]
[FONT=&quot]some efficacy for slowing or even regressing tumor growth.[/FONT]
[FONT=&quot]Such application was not long lived, however, as more[/FONT]
[FONT=&quot]realistic evaluations of the drug’s toxicity soon led to its[/FONT]
[FONT=&quot]abandonment in human medicine.[/FONT]
[FONT=&quot]By the mid-1970’s, methyltrienolone was becoming an[/FONT]
[FONT=&quot]accepted standard in non-human research studies,[/FONT]
[FONT=&quot]particularly those pertaining to the study of the androgen[/FONT]
[FONT=&quot]receptor activity. For this purpose the agent is very well[/FONT]
[FONT=&quot]suited. Its sheer potency and resistance to serum-binding[/FONT]
[FONT=&quot]proteins makes it an excellent in-vitro receptor-binding[/FONT]
[FONT=&quot]standard to compare other agents to. Being so resistant to[/FONT]
[FONT=&quot]metabolism, active methyltrienolone metabolites are also not[/FONT]
[FONT=&quot]going to greatly interfere with the results of most[/FONT]
[FONT=&quot]experiments. Body tissues can metabolize most steroids[/FONT]
[FONT=&quot]fairly easily, which means that even incubation studies can[/FONT]
[FONT=&quot]be complicated with the question of what is causing a[/FONT]
[FONT=&quot]particular effect, the steroid or one of its unidentified[/FONT]
[FONT=&quot]metabolites. This is much less of an issue with[/FONT]
[FONT=&quot]methyltrienolone. Today, methyltrienolone remains an agent[/FONT]
[FONT=&quot]of research use only.[/FONT]
[FONT=&quot]How Supplied:[/FONT]
[FONT=&quot]Methyltrienolone is not available as a commercial agent.[/FONT]
[FONT=&quot]Structural Characteristics:[/FONT]
[FONT=&quot]Methyltrienolone is a modified form of nandrolone. It differs[/FONT]
[FONT=&quot]by: 1) the addition of a methyl group at carbon 17- alpha to[/FONT]
[FONT=&quot]protect the hormone during oral administration and 2) the[/FONT]
[FONT=&quot]introduction of double bonds at carbons 9 and 11, which[/FONT]
[FONT=&quot]increases its binding affinity and slows its metabolism. The[/FONT]
[FONT=&quot]resulting steroid is significantly more potent than its[/FONT]
[FONT=&quot]nandrolone base, and displays a much longer half-life and[/FONT]
[FONT=&quot]lower affinity for serum-binding proteins in comparison.[/FONT]
[FONT=&quot]Methyltrienolone chemically differs from trenbolone only by[/FONT]
[FONT=&quot]the addition of a methyl group at c-17. This alteration[/FONT]
[FONT=&quot]changes the activity of methyltrienolone considerably,[/FONT]
[FONT=&quot]however, such that this agent should not simply be[/FONT]
[FONT=&quot]considered an oral form of trenbolone.[/FONT]
[FONT=&quot]Side Effects (Estrogenic):[/FONT]
[FONT=&quot]Methyltrienolone is not aromatized by the body, and is not[/FONT]
[FONT=&quot]measurably estrogenic. It is of note, however, that[/FONT]
[FONT=&quot]methyltrienolone displays significant binding affinity for the[/FONT]
[FONT=&quot]progesterone receptor.538 The side effects associated with[/FONT]
[FONT=&quot]progesterone are similar to those of estrogen, including[/FONT]
[FONT=&quot]negative feedback inhibition of testosterone production and[/FONT]
[FONT=&quot]enhanced rate of fat storage. Progestins also augment the[/FONT]
[FONT=&quot]stimulatory effect of estrogens on mammary tissue growth.[/FONT]
[FONT=&quot]There appears to be a strong synergy between these two[/FONT]
[FONT=&quot]hormones here, such that gynecomastia might even occur with[/FONT]
[FONT=&quot]the help of progestins, without excessive estrogen levels. The[/FONT]
[FONT=&quot]use of an anti-estrogen, which inhibits the estrogenic[/FONT]
[FONT=&quot]component of this disorder, is often sufficient to mitigate[/FONT]
[FONT=&quot]gynecomastia caused by progestational anabolic/androgenic[/FONT]
[FONT=&quot]steroids.[/FONT]
[FONT=&quot]Side Effects (Androgenic):[/FONT]
[FONT=&quot]Although classified as an anabolic steroid, androgenic side[/FONT]
[FONT=&quot]effects are still common with this substance. This may[/FONT]
[FONT=&quot]include bouts of oily skin, acne, and body/facial hair growth.[/FONT]
[FONT=&quot]Anabolic/androgenic steroids may also aggravate male[/FONT]
[FONT=&quot]pattern hair loss. Women are also warned of the potential[/FONT]
[FONT=&quot]virilizing effects of anabolic/androgenic steroids. These may[/FONT]
[FONT=&quot]include a deepening of the voice, menstrual irregularities,[/FONT]
[FONT=&quot]changes in skin texture, facial hair growth, and clitoral[/FONT]
[FONT=&quot]enlargement. Additionally, the 5-alpha reductase enzyme[/FONT]
[FONT=&quot]does not metabolize methyltrienolone, so its relative[/FONT]
[FONT=&quot]androgenicity is not affected by finasteride or dutasteride.[/FONT]
[FONT=&quot]Side Effects (Hepatotoxicity):[/FONT]
[FONT=&quot]Methyltrienolone is a c17-alpha alkylated compound. This[/FONT]
[FONT=&quot]alteration protects the drug from deactivation by the liver,[/FONT]
[FONT=&quot]allowing a very high percentage of the drug entry into the[/FONT]
[FONT=&quot]bloodstream following oral administration. C17-alpha[/FONT]
[FONT=&quot]alkylated anabolic/androgenic steroids can be hepatotoxic.[/FONT]
[FONT=&quot]Prolonged or high exposure may result in liver damage. In[/FONT]
[FONT=&quot]rare instances life-threatening dysfunction may develop. It is[/FONT]
[FONT=&quot]advisable to visit a physician periodically during each cycle[/FONT]
[FONT=&quot]to monitor liver function and overall health. Intake of c17-[/FONT]
[FONT=&quot]alpha alkylated steroids is commonly limited to 6-8 weeks,[/FONT]
[FONT=&quot]in an effort to avoid escalating liver strain.[/FONT]
[FONT=&quot]Methyltrienolone is an exceedingly potent oral steroid, with[/FONT]
[FONT=&quot]a very high level of resistance to hepatic metabolism. This[/FONT]
[FONT=&quot]makes methyltrienolone exceedingly liver-toxic, precluding[/FONT]
[FONT=&quot]its use as a prescription agent at this time, in any part of the[/FONT]
[FONT=&quot]world. Studies published from the University of Bonn[/FONT]
[FONT=&quot]Germany back in 1966 make this very clear.539 In fact, at this[/FONT]
[FONT=&quot]time researchers had deemed this the most liver-toxic steroid[/FONT]
[FONT=&quot]to ever be studied in humans, summing up their findings well[/FONT]
[FONT=&quot]when stating:[/FONT]
[FONT=&quot]“Methyltrienolone… which is orally active as an anabolic[/FONT]
[FONT=&quot]agent in a dose less than 1.0 mg per day in normal adults,has[/FONT]
[FONT=&quot]been tested with regard to its influence on liver function. As[/FONT]
[FONT=&quot]measured by multiple parameters (BSP retention; total[/FONT]
[FONT=&quot]bilirubin; activities of transaminases, alkaline phosphates[/FONT]
[FONT=&quot]and cholinesterase in serum; activity of proaccelerin in[/FONT]
[FONT=&quot]plasma) methyltrienolone turned out to be very active as to[/FONT]
[FONT=&quot]causing biochemical symptoms of intrahepatic cholestasis.[/FONT]
[FONT=&quot]…thus methyltrienolone at present being the most[/FONT]
[FONT=&quot]‘hepatotoxic’ steroid.”[/FONT]
[FONT=&quot]The use of a liver detoxification supplement such as Liver[/FONT]
[FONT=&quot]Stabil, Liv-52, or Essentiale Forte is advised while taking[/FONT]
[FONT=&quot]any hepatotoxic anabolic/androgenic steroids.[/FONT]
[FONT=&quot]Side Effects (Cardiovascular):[/FONT]
[FONT=&quot]Anabolic/androgenic steroids can have deleterious effects on[/FONT]
[FONT=&quot]serum cholesterol. This includes a tendency to reduce HDL[/FONT]
[FONT=&quot](good) cholesterol values and increase LDL (bad)[/FONT]
[FONT=&quot]cholesterol values, which may shift the HDL to LDL balance[/FONT]
[FONT=&quot]in a direction that favors greater risk of arteriosclerosis. The[/FONT]
[FONT=&quot]relative impact of an anabolic/androgenic steroid on serum[/FONT]
[FONT=&quot]lipids is dependant on the dose, route of administration (oral[/FONT]
[FONT=&quot]vs. injectable), type of steroid (aromatizable or nonaromatizable),[/FONT]
[FONT=&quot]and level of resistance to hepatic metabolism.[/FONT]
[FONT=&quot]Although not extensively studied in humans, the oral route,[/FONT]
[FONT=&quot]high relative potency, and non-aromatizable nature of[/FONT]
[FONT=&quot]methyltrienolone suggest that this agent is extremely prone to[/FONT]
[FONT=&quot]negatively altering lipid values and increasing atherogenic[/FONT]
[FONT=&quot]risk. Anabolic/androgenic steroids may also adversely affect[/FONT]
[FONT=&quot]blood pressure and triglycerides, reduce endothelial[/FONT]
[FONT=&quot]relaxation, and support left ventricular hypertrophy, all[/FONT]
[FONT=&quot]potentially increasing the risk of cardiovascular disease and[/FONT]
[FONT=&quot]myocardial infarction.[/FONT]
[FONT=&quot]To help reduce cardiovascular strain it is advised to[/FONT]
[FONT=&quot]maintain an active cardiovascular exercise program and[/FONT]
[FONT=&quot]minimize the intake of saturated fats, cholesterol, and simple[/FONT]
[FONT=&quot]carbohydrates at all times during active AAS administration.[/FONT]
[FONT=&quot]Supplementing with fish oils (4 grams per day) and a natural[/FONT]
[FONT=&quot]cholesterol/antioxidant formula such as Lipid Stabil or a[/FONT]
[FONT=&quot]product with comparable ingredients is also recommended.[/FONT]
[FONT=&quot]Side Effects (Testosterone Suppression):[/FONT]
[FONT=&quot]All anabolic/androgenic steroids when taken in doses[/FONT]
[FONT=&quot]sufficient to promote muscle gain are expected to suppress[/FONT]
[FONT=&quot]endogenous testosterone production. Without the intervention[/FONT]
[FONT=&quot]of testosterone-stimulating substances, testosterone levels[/FONT]
[FONT=&quot]should return to normal within 1-4 months of drug secession.[/FONT]
[FONT=&quot]Note that prolonged hypogonadotrophic hypogonadism can[/FONT]
[FONT=&quot]develop secondary to steroid abuse, necessitating medical[/FONT]
[FONT=&quot]intervention.[/FONT]
[FONT=&quot]Administration (General):[/FONT]
[FONT=&quot]Studies have shown that taking an oral anabolic steroid with[/FONT]
[FONT=&quot]food may decrease its bioavailability.540 This is caused by[/FONT]
[FONT=&quot]the fat-soluble nature of steroid hormones, which can allow[/FONT]
[FONT=&quot]some of the drug to dissolve with undigested dietary fat,[/FONT]
[FONT=&quot]reducing its absorption from the gastrointestinal tract. For[/FONT]
[FONT=&quot]maximum utilization, methyltrienolone should be taken on an[/FONT]
[FONT=&quot]empty stomach.[/FONT]
[FONT=&quot]Administration (Men):[/FONT]
[FONT=&quot]Methyltrienolone is no longer used in clinical medicine due[/FONT]
[FONT=&quot]to an unacceptable level of hepatotoxicity. This agent is[/FONT]
[FONT=&quot]generally not recommended for physique- or performance[/FONT]
[FONT=&quot]enhancing purposes for the same reason. Those absolutely[/FONT]
[FONT=&quot]insisting on its use need to take its level of liver toxicity very[/FONT]
[FONT=&quot]seriously. At the very least, routine blood tests should be[/FONT]
[FONT=&quot]conducted to ensure the agent is not imparting damage. Drug[/FONT]
[FONT=&quot]duration should also be very limited, preferably to 4 weeks[/FONT]
[FONT=&quot]of use or less. The relative potency of methyltrienolone is[/FONT]
[FONT=&quot]extremely high, requiring doses as little as .5 milligram per[/FONT]
[FONT=&quot]day. Its effective and tolerable range is usually considered to[/FONT]
[FONT=&quot]be .5 to 2mg per day. Dianabol-type doses of 20-30 mg daily[/FONT]
[FONT=&quot]are completely unthinkable, and should never be attempted.[/FONT]
[FONT=&quot]Again, this is an extremely toxic steroid, and all good advice[/FONT]
[FONT=&quot]would say to avoid it. Any one of the many commercially[/FONT]
[FONT=&quot]available steroids would be much safer choices.[/FONT]
[FONT=&quot]Administration (Women):[/FONT]
[FONT=&quot]Methyltrienolone is no longer used in clinical medicine due[/FONT]
[FONT=&quot]to an unacceptable level of hepatotoxicity. This agent is not[/FONT]
[FONT=&quot]recommended for women for physique- or performanceenhancing[/FONT]
[FONT=&quot]purposes due to its extremely strong toxicity and[/FONT]
[FONT=&quot]tendency to produce virilizing side effects.[/FONT]
[FONT=&quot]Availability:[/FONT]
[FONT=&quot]Methyltrienolone is not produced as a prescription steroid[/FONT]
[FONT=&quot]product in any part of the world. With the rapid expansion of[/FONT]
[FONT=&quot]underground steroid manufacturers, this agent has been[/FONT]
[FONT=&quot]released as a black market designer compound. Those[/FONT]
[FONT=&quot]contemplating the use of underground forms of[/FONT]
[FONT=&quot]methyltrienolone should consider that such agents are being[/FONT]
[FONT=&quot]released for human use without any government approval or[/FONT]
[FONT=&quot]consideration to its safety[/FONT][FONT=&quot][/FONT]
<!--[if gte mso 9]><xml> <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true" DefSemiHidden="true" DefQFormat="false" DefPriority="99" LatentStyleCount="267"> <w:LsdException Locked="false" Priority="1" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Normal"/> <w:LsdException Locked="false" Priority="9" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="heading 1"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/> <w:LsdException Locked="false" Priority="39" Name="toc 1"/> <w:LsdException Locked="false" Priority="39" Name="toc 2"/> <w:LsdException Locked="false" Priority="39" Name="toc 3"/> <w:LsdException Locked="false" Priority="39" Name="toc 4"/> <w:LsdException Locked="false" Priority="39" Name="toc 5"/> <w:LsdException Locked="false" Priority="39" Name="toc 6"/> <w:LsdException Locked="false" Priority="39" Name="toc 7"/> <w:LsdException Locked="false" Priority="39" Name="toc 8"/> <w:LsdException Locked="false" Priority="39" Name="toc 9"/> <w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/> <w:LsdException Locked="false" Priority="10" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Title"/> <w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/> <w:LsdException Locked="false" Priority="11" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/> <w:LsdException Locked="false" Priority="22" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Strong"/> <w:LsdException Locked="false" Priority="20" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/> <w:LsdException Locked="false" Priority="59" SemiHidden="false" UnhideWhenUsed="false" Name="Table Grid"/> <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/> <w:LsdException Locked="false" Priority="1" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 1"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 1"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 1"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/> <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/> <w:LsdException Locked="false" Priority="34" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/> <w:LsdException Locked="false" Priority="29" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Quote"/> <w:LsdException Locked="false" Priority="30" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 1"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 1"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 2"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 2"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 2"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 2"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 2"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 3"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 3"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 3"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 3"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 3"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 4"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 4"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 4"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 4"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 4"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 5"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 5"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 5"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 5"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 5"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 6"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 6"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 6"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 6"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 6"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/> <w:LsdException Locked="false" Priority="19" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/> <w:LsdException Locked="false" Priority="21" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/> <w:LsdException Locked="false" Priority="31" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/> <w:LsdException Locked="false" Priority="32" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/> <w:LsdException Locked="false" Priority="33" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Book Title"/> <w:LsdException Locked="false" Priority="37" Name="Bibliography"/> <w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/> </w:LatentStyles> </xml><![endif]--><!--[if gte mso 10]> <style> /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-qformat:yes; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin-top:0in; mso-para-margin-right:0in; mso-para-margin-bottom:10.0pt; mso-para-margin-left:0in; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri","sans-serif"; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin;} </style> <![endif]-->
 
This stuff in dosed in MCG .... I would never touch it for fear of it being overdosed. On paper the rating is pretty crazy.
 
I have a LOT of this stuff. Haven't used it yet. Might give it a 2-3 week blast as a trial run if I like it I will run it pre-competition.
 
i didn't even know that Kalpa made Metribolone. thanks for letting me know, i won't be trying them out. i'd like to try Alpha Pharma's. at least they have their shit together in India lol

what does that mean? Kalpa doesnt have their shit together? just curious , and wondering who has tried this metribolone
 
Back
Top